bioMerieux S.A.

Co. specializes in the field of in vitro diagnostics for clinical and industrial applications. Co. designs, develops, manufactures and markets systems used in: Clinical Applications (the diagnosis of infectious diseases such as hepatitis, HIV, tuberculosis and respiratory illnesses, as well as pathologies such as cardiovascular diseases and cancers, based on the analysis of biological samples such as blood, saliva or urine); and Industrial Applications (microbiological analysis of samples of finished or semi-finished products (or of the environment), chiefly in the food processing and biopharmaceutical industries), detecting microorganisms in agri-food, pharmaceutical and cosmetic products.
  • TickerBIM
  • ISINFR0013280286
  • ExchangeEuronext Paris
  • SectorHealth Care Equipment & Services
  • CountryFrance

Analysts

Hugo Solvet

BIOMÉRIEUX - NEUTRAL | EUR66(-4%) BIM steps up its footprint in China

BIOMÉRIEUX - NEUTRAL | EUR66(-4%) BIM steps up its footprint in China Acquisition of majority stake in Chinese immunoassay player Going deeper with access to Tier 2 Chinese hospitals High price for rare and stable assets (c.7.5x EV/Sales 2019)

Hugo Solvet

BIOMÉRIEUX - NEUTRAL | EUR66(-4%) BIM steps up its footprint in China

BIOMÉRIEUX - NEUTRAL | EUR66(-4%) BIM steps up its footprint in China Acquisition of majority stake in Chinese immunoassay player Going deeper with access to Tier 2 Chinese hospitals High price for rare and stable assets (c.7.5x EV/Sales 2019)

Hugo Solvet

BIOMÉRIEUX PALMETTO still circling around FilmArray (feedback from conference call)

NEUTRAL | EUR67 vs. 70 Impact from Medicare contractors on RP Panel: -4% EPS cut Awaiting PALMETTO to draft decision on GI test (+200bp cut?) Reimb. pressure rolling into commercial payers and inpatients Some reassuring comments on Immunoassays and China Including a higher than expected impact on RP panel to our ests. Read more >

Michael Waterhouse

Morningstar | BioMerieux’s 3Q Top-Line Growth Holds Few Surprises

BioMerieux reported 8.8% organic revenue growth during the quarter that puts the company on track to meet our year-end forecast. For now, we're retaining our fair value estimate and narrow moat rating.  While we don't anticipate a change to our projections for this year, we could be underestimating growth for next year, especially if the FilmArray product line can sustain anywhere near the slightly better-than-expected 38% growth it posted during this quarter. While we still think FilmArray has a nice trajectory ahead, owing to customer adoption, menu expansion, and international expansion, w...

Michael Waterhouse

BioMerieux’s 3Q Top-Line Growth Holds Few Surprises

BioMerieux reported 8.8% organic revenue growth during the quarter that puts the company on track to meet our year-end forecast. For now, we're retaining our fair value estimate and narrow moat rating. While we don't anticipate a change to our projections for this year, we could be underestimating growth for next year, especially if the FilmArray product line can sustain anywhere near the slightly better-than-expected 38% growth it posted during this quarter. While we still think FilmArray has a...

Thibaut Voglimacci-Stephanopoli

INVEST SECURITIES - Biomerieux : Au-delà du T3, l'ombre de Palmetto plane toujours - VENTE, 55€ vs 57€

Alors que la publication du T3 est ressortie dans la lignée des dernières publications avec une croissance lfl dynamique (+8,8% lfl), celle-ci n'entraine pas de profondes révisions. Nous actualisons principalement nos estimations de CA de FilmArray que nous réduisons de -15% en moyenne afin d'intégrer l'impact estimé à long terme de Palmetto. Après actualisation du modèle, notre OC est abaissé à 55€ (vs 57€). Nous réitérons notre opinion VENTE qui repose sur les inquiétudes sur le marché US avec comme point d'inflexion l'année 2018. L'impact de la décision de Palmetto, dans le prolongement de ...

1 director sold

A director at Biomerieux sold 10,000 shares at 75.584EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of bo...

Alex Koagne ...
  • Christophe Chaput
  • Christophe-Raphaël Ganet
  • Jean Sassus
  • Olfa Taamallah
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 10/15/2018

...

Ahmed Ben Salem ...
  • Bruno Cavalier
  • Christophe-Raphaël Ganet
  • Emira Sagaama
  • Jean Sassus
  • Laure Billoret
  • Matthias Desmarais
  • Steven Gould
  • Valentin Pernet
  • Yassine Batini

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 10/15/2018

...

Ahmed Ben Salem ...
  • Bruno Cavalier
  • Christophe-Raphaël Ganet
  • Emira Sagaama
  • Jean Sassus
  • Laure Billoret
  • Matthias Desmarais
  • Steven Gould
  • Valentin Pernet
  • Yassine Batini

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 15/10/2018

...

Alex Koagne ...
  • Christophe Chaput
  • Christophe-Raphaël Ganet
  • Jean Sassus
  • Olfa Taamallah
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 15/10/2018

...

Bruno Cavalier ...
  • Christophe-Raphaël Ganet
  • Jean Sassus
  • Khaled Ben Amor
  • Laurence Hofmann
  • Louis Boujard
  • Olfa Taamallah
  • Philippe Ourpatian
  • Pierre Tegner
  • Steven Gould
  • Yan Derocles

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 10/08/2018

...

An unfavourable environment weighs on BIOMERIEUX SA, which sees a downgrade to Slightly Negative

The independent financial analyst theScreener just requalified the general evaluation of BIOMERIEUX SA (FR), active in the Medical Equipment industry. As regards its fundamental valuation, the title still shows 1 out of 4 stars and its market behaviour is seen as moderately risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Slightly Negative. As of the analysis date October 9, 2018, the closing price was EUR 62.30 and its target price was estimated at EUR 59.18.

GlobalData Department

bioMerieux SA (BIM) - Medical Equipment - Deals and Alliances Profile

Summary bioMerieux SA (bioMerieux), a subsidiary of Institut Merieux SA, develops, manufactures and markets in vitro diagnostic solutions for private and hospital laboratories. The company offers diagnostic solutions such as systems, reagents and software. Its products are used to diagnose infectious diseases, cardiovascular diseases and targeted cancers. The company also provides solutions for the enumeration of microbial flora, to detect specific pathogenic bacteria, and to monitor air and surface quality and sterility testing for agri-food, cosmetics and pharmaceutical industries. The comp...

Anaïs Dudout

Proxy Report - 17/05/2018

La fin de l'exercice 2017 fût marquée par la nomination d'Alexandre Mérieux, ancien Directeur Général Délégué de la société, en qualité de Président-Directeur Général pour succéder à Jean-Luc Bélingard. Il est regrettable que la société n'ait pas profité de ce changement au sein de la direction pour séparer les fonctions de Président et de Directeur Général. Cette année encore, Proxinvest ne soutiendra pas la rémunération attribuée à Jean-Luc Bélingard et Alexandre Mérieux pour des raisons similaires à l'année dernière (Résolution 10 et 11) : une rémunération différée revue à la hausse sur la...

Jérôme VINERIER

Analyse court terme - BIOMERIEUX : La reprise est une consolidation.

La tendance de fond est clairement orientée à la baisse. Le MACD est négatif, il confirme cette tendance. La reprise est une consolidation qui va buter sur 70,40 € prochainement. Le prochain objectif est à 63,02 €, puis 58,70 €. Le franchissement de 74,56 € remettrait en cause la suite de la baisse.

Jérôme VINERIER

Short term view - BIOMERIEUX : Rising consolidation.

The background trend is clearly bearish. The negative MACD confirms the trend. The rise is a consolidation that will soon bump against the level at €70.40. The next target is at €63.02, then €58.70. Passing €74.56 would question the continuation of the fall.

Jérôme VINERIER

Analyse court terme - BIOMERIEUX : La tendance est baissière.

La tendance est baissière. Les prix baissent à nouveau, mais le mouvement est devenu hésitant. Le prochain support est à 63,02 €. La tendance baissière serait remise en cause au-dessus de 74,56 €.

Jérôme VINERIER

Short term view - BIOMERIEUX : The trend is bearish.

The trend is bearish. Prices are falling again, but the movement has become hesitant. The next support is at €63.02. The bearish trend would be challenged above €74.56.

Jérôme VINERIER

Analyse moyen terme - BIOMERIEUX : La tendance est incertaine.

La tendance est incertaine. Les cours baissent, et il y a une possibilité d'accélération baissière. Une nouvelle tendance baissière tente de démarrer.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch